SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Alteogen signs option and license pact with Novartis for Hybrozyme-enabled products

Alteogen entered an option and license agreement with Novartis covering development and commercialization of Hybrozyme™-enabled subcutaneous products.

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories